Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Receivables - Other for 3 consecutive years, with $727000.0 as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Other changed N/A to $727000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $727000.0, a N/A change, with the full-year FY2024 number at $41000.0, down 93.25% from a year prior.
- Receivables - Other was $727000.0 for Q3 2025 at Inhibrx Biosciences, roughly flat from $730000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $952000.0 in Q2 2024 to a low of $41000.0 in Q4 2024.
- A 3-year average of $611400.0 and a median of $727000.0 in 2025 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: crashed 93.25% in 2024, then decreased 23.32% in 2025.
- Inhibrx Biosciences' Receivables - Other stood at $607000.0 in 2023, then plummeted by 93.25% to $41000.0 in 2024, then skyrocketed by 1673.17% to $727000.0 in 2025.
- Per Business Quant, the three most recent readings for INBX's Receivables - Other are $727000.0 (Q3 2025), $730000.0 (Q2 2025), and $41000.0 (Q4 2024).